Results 31 to 40 of about 21,093,248 (119)

IgG4‐Related Disease Mimicking Metastatic Malignancy: Polyserositis and Abdominal Lymphadenopathy

Clinical Case Reports, Volume 13, Issue 7, July 2025.
ABSTRACT In patients presenting with multiple space‐occupying lesions, preserved general condition, and normal or mildly elevated tumor markers, IgG4‐related disease (IgG4‐RD) should be considered in the differential diagnosis. We report an extremely unusual case of IgG4‐RD mimicking metastatic malignancy, with polyserositis and widespread abdominal ...
Meisi Huo, Jinhua Li, Shuqi Wu, Shiyan Yan   +3 more
wiley   +1 more source

Systematic Review of Management Strategies for Alport Syndrome: Implications for Male Patients

Health Science Reports, Volume 8, Issue 4, April 2025.
ABSTRACT Background and Aims Alport Syndrome (AS) is a rare genetic disorder characterized by progressive kidney disease, hearing loss, and ocular abnormalities, with an incidence of approximately 1 in 50,000 newborns. Due to the severity of the disease, particularly in males with X‐linked inheritance, this systematic review consolidates current ...
Zouina Sarfraz, Ayesha Khan, Maryyam Liaqat, Aden Khan, Faheem Javad, Meher Saleem, Azza Sarfraz, Musfira Khalid, Muzna Sarfraz, Manish Kc, Omar Irfan   +10 more
wiley   +1 more source

Simultaneous Spectrophotometric Estimation of Telmisartan and Amlodipine Besylate in Tablet Dosage Form [PDF]

, 2015
A simple, accurate and reproducible spectrophotometric methods have been developed for the simultaneous estimation of Telmisartan (TEL) and Amlodipine Besylate (AML) in combined tablet dosage forms.
A. Peepliwal, Peepliwal, A., D. S. Rathore, Gupta, P., P. Gupta, N. K. Gupta, Gupta, N. K., Rathore, D. S.   +7 more
core   +1 more source

Part 2: Drug Interactions Involving Cannabis Products in Persons Aged 18 and Over: A Summary of Published Case Reports and Analysis of the FDA Adverse Event Reporting System

Pharmacology Research &Perspectives, Volume 13, Issue 1, February 2025.
ABSTRACT The increasing utilization of cannabis products combined with lack of data regarding potential cannabis–prescription drug interactions is concerning. This study aimed to review published case reports and FDA Adverse Event Reporting System (FAERS) spontaneous reports to assess cannabis–drug interactions in persons aged 18 and over. A literature
Maryann R. Chapin, Sandra L. Kane‐Gill, Xiaotong Li, Kojo Abanyie, Sanya B. Taneja, Susan Egbert, Mary F. Paine, Richard D. Boyce   +7 more
wiley   +1 more source

Simultaneous Estimation of Amlodipine Besylate and Nebivolol Hydrochloride in Pharmaceutical Tablets Formulation by RP-HPLC Using PDA Detector: Simultaneous estimation of amlodipine besylate and nebivolol hydrochloride

, 2018
The present work was undertaken with the aim to develop and validate a rapid and consistent RP-HPLC method in which the peaks will be appear with short period of time as per ICH Guidelines.The separation was achieved on a stainless steel analytical ...
Ashutosh Kumar, Manidipa Debnath, Mendeli Sreenu, Mahesh Kumar Singh   +3 more
core   +1 more source

Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis

, 2015
Philipp Sievers,1 Lorenz Uhlmann,2 Sevil Korkmaz-Icöz,3 Christian Fastner,1 Florian Bea,1 Erwin Blessing,1 Hugo A Katus,1 Michael R Preusch11Department of Internal Medicine III, 2Institute of Medical Biometry and Informatics, 3Department of ...
Katus HA, Preusch MR, Bea F, Blessing E, Korkmaz-Icöz S, Fastner C, Uhlmann L, Sievers P   +7 more
core  

Investigation of forced and total degradation products of amlodipine besylate by liquid chromatography and liquid chromatography-mass spectrometry [PDF]

, 2014
An isocratic, reversed-phase liquid chromatographic method was applied for the investigation of the degradation products of amlodipine besylate under the stressed conditions in solution. Amlodipine besylate stock solutions were subjected to acid
Ivić Avramov Milka L., Petrović Slobodan D., Đurić Svetlana Lj., Stoiljković Zora Ž., Mijin Dušan Ž., Jadranin Milka B.   +5 more
core   +1 more source

Efficacy of Olmesartan/Amlodipine Single‐Pill Combination on 24‐h Mean Systolic Blood Pressure Measured by Ambulatory Monitoring in Non‐Responders to Valsartan or Candesartan Monotherapy

The Journal of Clinical Hypertension, Volume 27, Issue 1, January 2025.
ABSTRACT The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single‐pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in non‐responders to valsartan or candesartan monotherapy. Isolated systolic hypertension (ISH) is the most prevalent form of hypertension in middle‐aged and elderly ...
Woo‐Baek Chung, Sang‐Hyun Ihm, Yun‐Seok Choi, Ho‐Joong Youn   +3 more
wiley   +1 more source

Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study)

The Journal of Clinical Hypertension, Volume 27, Issue 1, January 2025.
ABSTRACT Sacubitril/valsartan, an angiotensin receptor‐neprilysin inhibitor, has demonstrated a superior blood pressure‐lowering effect compared with renin‐angiotensin system inhibitors in several clinical trials. However, there has been no available evidence on the comparison between sacubitril/valsartan and calcium channel blockers (CCBs), a well ...
Koichi Yamamoto, Daisuke Yarimizu, Ayano Shimanishi, Shunsuke Eguchi, Kazuma Iekushi, Yoichi Takami, Yoichi Nozato, Kazuomi Kario, Hiromi Rakugi   +8 more
wiley   +1 more source

Bioequivalence evaluation of two amlodipine salts, besylate and orotate, each in a fixed-dose combination with olmesartan in healthy subjects

, 2015
Soo-Yun Lee,1 Jung-Ryul Kim,2,3 Jin Ah Jung,4 Wooseong Huh,2,5 Mi Young Bahng,6 Jae-Wook Ko1,2 1Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea; 2Department of Clinical Pharmacology and ...
Jung JA, Lee SY, Bahng MY, Ko JW, Kim JR, Huh W   +5 more
core